NCT05496426

A Study of KL130008 in Adults With Severe Alopecia Areata

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Trial Evaluating the Safety and Efficacy of KL130008 Capsule in Patients With Severe Alopecia Areata

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 176 (estimated)
• Sponsor: Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess KL130008 is safe and effective in adults with severe alopecia areata

Detailed description

This is a multi-center Phase 2 study to evaluate the safety and effectiveness of an investigational drug in adults (≥18 years and ≤65 years) who have 50% or greater scalp hair loss, including alopecia totalis (AT) and alopecia universalis (AU).

Conditions

• Alopecia Areata

Interventions

Type	Name	Description
DRUG	KL130008/Placebo	Drug: KL130008 Drug: Placebo

Timeline

• Start date: 2022-10-31
• Primary completion: 2024-12-31
• Completion: 2024-12-31
• First posted: 2022-08-11
• Last updated: 2022-08-11

Locations

1 site across 1 country: China